RhumbLine Advisers’s Arcturus Therapeutics ARCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $522K | Buy |
40,137
+6,636
| +20% | +$86.3K | ﹤0.01% | 2658 |
|
|
2025
Q1 | $355K | Buy |
33,501
+457
| +1% | +$4.84K | ﹤0.01% | 2793 |
|
|
2024
Q4 | $561K | Buy |
33,044
+47
| +0.1% | +$798 | ﹤0.01% | 2610 |
|
|
2024
Q3 | $766K | Sell |
32,997
-1,189
| -3% | -$27.6K | ﹤0.01% | 2410 |
|
|
2024
Q2 | $832K | Sell |
34,186
-3,382
| -9% | -$82.4K | ﹤0.01% | 2340 |
|
|
2024
Q1 | $1.27M | Buy |
37,568
+1,409
| +4% | +$47.6K | ﹤0.01% | 2126 |
|
|
2023
Q4 | $1.14M | Sell |
36,159
-278
| -0.8% | -$8.77K | ﹤0.01% | 2188 |
|
|
2023
Q3 | $931K | Buy |
36,437
+675
| +2% | +$17.2K | ﹤0.01% | 2251 |
|
|
2023
Q2 | $1.03M | Buy |
35,762
+5,363
| +18% | +$154K | ﹤0.01% | 2269 |
|
|
2023
Q1 | $729K | Buy |
30,399
+1,219
| +4% | +$29.2K | ﹤0.01% | 2269 |
|
|
2022
Q4 | $495K | Buy |
29,180
+915
| +3% | +$15.5K | ﹤0.01% | 2465 |
|
|
2022
Q3 | $419K | Buy |
28,265
+2,567
| +10% | +$38.1K | ﹤0.01% | 2574 |
|
|
2022
Q2 | $404K | Sell |
25,698
-1,229
| -5% | -$19.3K | ﹤0.01% | 2607 |
|
|
2022
Q1 | $726K | Sell |
26,927
-2,412
| -8% | -$65K | ﹤0.01% | 2268 |
|
|
2021
Q4 | $1.09M | Sell |
29,339
-303
| -1% | -$11.2K | ﹤0.01% | 2172 |
|
|
2021
Q3 | $1.42M | Buy |
29,642
+975
| +3% | +$46.6K | ﹤0.01% | 2069 |
|
|
2021
Q2 | $970K | Buy |
28,667
+7,287
| +34% | +$247K | ﹤0.01% | 2261 |
|
|
2021
Q1 | $883K | Sell |
21,380
-3,453
| -14% | -$143K | ﹤0.01% | 2237 |
|
|
2020
Q4 | $1.08M | Buy |
24,833
+7,969
| +47% | +$346K | ﹤0.01% | 2098 |
|
|
2020
Q3 | $723K | Sell |
16,864
-459
| -3% | -$19.7K | ﹤0.01% | 2121 |
|
|
2020
Q2 | $810K | Buy |
+17,323
| New | +$810K | ﹤0.01% | 2128 |
|